Zura Bio Limited (ZURA)
- Previous Close
3.9700 - Open
4.0100 - Bid 4.0500 x 100
- Ask 4.0900 x 200
- Day's Range
3.9100 - 4.1700 - 52 Week Range
2.0000 - 7.2200 - Volume
393,346 - Avg. Volume
478,690 - Market Cap (intraday)
259.561M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
7.14 - EPS (TTM)
0.5700 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.43
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
zurabio.comRecent News: ZURA
View MorePerformance Overview: ZURA
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZURA
View MoreValuation Measures
Market Cap
259.56M
Enterprise Value
259.90M
Trailing P/E
7.14
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.99%
Return on Equity (ttm)
-26.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.94M
Diluted EPS (ttm)
0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
188.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-28.05M